Bacteriocins as Potential Anticancer Agents

Kaur, Sumanpreet

doi:10.3389/fphar.2015.00272

Cited by 211 publications

(206 citation statements)

References 89 publications

(101 reference statements)

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…In this trend, the number of reports concerning bacteriocins as antiprotozoal agents (20)(21)(22)(23) is surprisingly lower than that of reports aiming at other eukaryotic targets such as fungi (24)(25)(26) or even tumoral cells (27)(28)(29).…”

mentioning

confidence: 77%

Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents

Abengózar

Cebrián

Saugar

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We report the feasibility of enterocin AS-48, a circular cationic peptide produced by Enterococcus faecalis, as a new leishmanicidal agent. AS-48 is lethal to Leishmania promastigotes as well as to axenic and intracellular amastigotes at low micromolar concentrations, with scarce cytotoxicity to macrophages. AS-48 induced a fast bioenergetic collapse of L. donovani promastigotes but only a partial permeation of their plasma membrane with limited entrance of vital dyes, even at concentrations beyond its full lethality. Fluoresceinated AS-48 was visualized inside parasites by confocal microscopy and seen to cause mitochondrial depolarization and reactive oxygen species production. Altogether, AS-48 appeared to have a mixed leishmanicidal mechanism that includes both plasma membrane permeabilization and additional intracellular targets, with mitochondrial dysfunctionality being of special relevance. This complex leishmanicidal mechanism of AS-48 persisted even for the killing of intracellular amastigotes, as evidenced by transmission electron microscopy. We demonstrated the potentiality of AS-48 as a new and safe leishmanicidal agent, expanding the growing repertoire of eukaryotic targets for bacteriocins, and our results provide a proof of mechanism for the search of new leishmanicidal bacteriocins, whose diversity constitutes an almost endless source for new structures at moderate production cost and whose safe use on food preservation is well established.

show abstract

mentioning

confidence: 77%

Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents

Abengózar

Cebrián

Saugar

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Recent studies have indicated the activity of bacteriocins against some tumor cell lines in vitro [22]. Colicin A and E1 produced by E. coli demonstrated growth inhibition of human fibroblast, bone, breast and colon cancer cells amongst other cell lines in vitro [46]. Colicin D and E3 was shown to induce a dose dependent inhibition of murine leukemia cells at 0.4, 0.8, 1.6 and 3.2 mg/mL in vitro [36].…”

Section: Anti-cancer Activitymentioning

confidence: 99%

“…Bacteriocins with anticancer activity appear to be cationic, amphiphilic and membrane active with cytoxicity due to necrotic cell membrane lysis induced by increased presence of negatively charged molecules on the membrane surface [7]. Additionally, cancer cells have higher membrane fluidity compared to normal cells allowing for membrane destabilization [46]. Moreover, other bacteriocins are known to affect angiogenesis, subsequent cancer progression, disrupt the integrity of mitochondrial membrane and induce apoptosis and cell cycle arrest in cancer cells [49].…”

Section: Anti-cancer Activitymentioning

confidence: 99%

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Slattery²,

2020

View full text Add to dashboard Cite

Despite highly specialized international interventions and policies in place today, the rapid emergence and dissemination of resistant bacterial species continue to occur globally, threatening the longevity of antibiotics in the medical sector. In particular, problematic nosocomial infections caused by multidrug resistant Gram-negative pathogens present as a major burden to both patients and healthcare systems, with annual mortality rates incrementally rising. Bacteriocins, peptidic toxins produced by bacteria, offer promising potential as substitutes or conjugates to current therapeutic compounds. These non-toxic peptides exhibit significant potency against certain bacteria (including multidrug-resistant species), while producer strains remain insusceptible to the bactericidal peptides. The selectivity and safety profile of bacteriocins have been highlighted as superior advantages over traditional antibiotics; however, many aspects regarding their efficacy are still unknown. Although active at low concentrations, bacteriocins typically have low in vivo stability, being susceptible to degradation by proteolytic enzymes. Another major drawback lies in the feasibility of large-scale production, with these key features collectively limiting their current clinical application. Though such limitations require extensive research, the concept of expanding bacteriocins from food preservation to human health opens many fascinating doors, including novel drug delivery systems and anticancer treatment applications.

show abstract

“…There have been some suggestions that bacteriocins can be employed as anticancer agents, either through their impact on cancerous cells or through the inhibition of bacteria associated with the initiation of disease 60 . One such study focused on the impact of nisin on head and neck squamous cell carcinoma (HNSCC) cell apoptosis and cell proliferation in vitro and in vivo in murine oral cancer 61 .…”

Section: Novel Health Targets For Bacteriocinsmentioning

confidence: 99%

Bacteriocin production: a relatively unharnessed probiotic trait?

et al. 2016

View full text Add to dashboard Cite

Probiotics are “live microorganisms which, when consumed in adequate amounts, confer a health benefit to the host”. A number of attributes are highly sought after among these microorganisms, including immunomodulation, epithelial barrier maintenance, competitive exclusion, production of short-chain fatty acids, and bile salt metabolism. Bacteriocin production is also generally regarded as a probiotic trait, but it can be argued that, in contrast to other traits, it is often considered a feature that is desirable, rather than a key probiotic trait. As such, the true potential of these antimicrobials has yet to be realised.

show abstract

Bacteriocins as Potential Anticancer Agents

Cited by 211 publications

References 89 publications

Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents

Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Bacteriocin production: a relatively unharnessed probiotic trait?

Contact Info

Product

Resources

About